ADT is a provider of monitored security and interactive home and business automation solutions in the United States and Canada. The company's monitored security and automation offerings involve the installation and monitoring of security and premises automation systems designed to detect intrusion; control access; sense movement, smoke, fire, carbon monoxide, flooding, temperature, and other environmental conditions and hazards; and address personal emergencies. The company's products and services include interactive technologies to allow its customers to remotely monitor and manage their residential and commercial environments by adding automation capabilities to its monitored security systems.

Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. The company's product, TIBSOVO? (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. The company's other product is IDHIFA? (enasidenib) for patients with R/R AML and an IDH2 mutation. The company's pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a.

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference (RNAi). RNAi is a biological pathway within cells for sequence-specific silencing and regulation of gene expression. The company has two RNAi-based medicines, ONPATTRO? (patisiran) and GIVLAARI? (givosiran). ONPATTRO is approved by the United States Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and has also been approved in the European Union, Japan, Canada and Switzerland. GIVLAARI is approved by FDA for the treatment of adults with acute hepatic porphyria.

BioCryst Pharmaceuticals is a biotechnology company that discovers oral, small-molecule medicines. The company focuses on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the main role in the biological pathway of the disease. The company's drug/drug candidates include: Berotralstat (BCX7353), an oral serine protease inhibitor targeting kallikrein that is being developed as a once-daily oral therapy for the prevention of Hereditary Angioedema; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; and BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive.

Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. The company's target indications include diseases, such as Alzheimer's disease and Parkinson's disease, as well as orphan indications, such as mucopolysaccharidosis type II, and amyotrophic lateral sclerosis. The company's Transport Vehicle technology enables several classes of biotherapeutics to cross the blood-brain barrier (BBB), including enzymes, antibodies, proteins and oligonucleotides. This technology is designed to engage BBB transport receptors, which are expressed in brain capillaries and facilitate transport of proteins into the brain.

Harrow Health focuses on the development, production and sale of medications. The company mainly focuses on its ImprimisRx business, which is an ophthalmology pharmaceutical compounding business, and Park Compounding, Inc., which is a pharmacy focused primarily on health and wellness related, customizable pharmaceutical compounding. The company's other subsidiaries include: Eton Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products utilizing the U.S. Food and Drug Administration 505(b)(2) regulatory pathway; and Surface Pharmaceuticals, Inc., a pharmaceutical company focused on development and commercialization of therapeutics for ocular surface diseases.

MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a portable inhaler.

Ryanair Holdings is a holding company. Through its subsidiaries, Co. operates an ultra-low cost, scheduled-passenger airline serving short-haul, point-to-point routes between Ireland, the U.K., Continental Europe, and Morocco. Co. offers over 2,000 scheduled short-haul flights per day serving approximately 210 airports throughout Europe, and flying approximately 1,600 routes. In addition, Co. provides various ancillary services and engages in other activities connected with its core air passenger service, including non-flight scheduled services, Internet-related services, and the in-flight sale of beverages, food, and merchandise.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of diseases. The company is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA and other neuromuscular and central nervous system. The company's commercial product, EXONDYS 51? (eteplirsen) Injection is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

Spirit AeroSystems Holdings is an independent non-Original Equipment Manufacturer commercial aerostructures designer and manufacturer. The company has three segments: Fuselage Systems, which includes development, production and marketing of forward, mid and rear fuselage sections and systems, and related spares and maintenance, repair, and overhaul (MRO) services; Propulsion Systems, which includes development, production and marketing of struts/pylons, nacelles, and related engine structural components, and related spares and MRO services; and Wing Systems, which includes development, production and marketing of wings and wing components, as well as related spares and MRO services.

Twist Bioscience is a synthetic biology company. The company is developing a disruptive DNA synthesis platform to industrialize the engineering of biology. The main of its platform is a proprietary technology that manufactures synthetic DNA by writing DNA on a silicon chip. The company has combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create a technology platform. The company's offerings consists of two primary products that address different needs of its customers across a variety of applications: synthetic genes, oligonucleotide (oligo) pools, next generation sequencing tools and DNA libraries.

Vectrus provides facility and logistics services and information technology and network communications services in Asia, Europe, the Middle East and the U.S. The company's facility and logistics services consist of airfield management, ammunition management, civil engineering, communications, emergency services, equipment maintenance, repair and services, life support activities, public works, security, transportation operations, and warehouse management and distribution. The company's information technology and network communications services consist of communications, management and service support, network and cyber security, systems installation and activation and mission support.